NASDAQ · MRUS
Healthcare · Biotechnology
$90.00
Up+$0.00 (+0.00%)
Updated Sep 10, 2026, 9:25 PM
SID Score
5.5/10
Composite research score
Smart Money
50/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MRUS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning MRUS.
MRUS research
Company profile and research snapshot.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2025 | Leerink Partners | Market Perform | — |
| Sep 30, 2025 | Wells Fargo | Equal-Weight | — |
| Sep 30, 2025 | Canaccord Genuity | Hold | — |
| Sep 30, 2025 | Guggenheim | Neutral | — |
| Sep 30, 2025 | LifeSci Capital | Market Perform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 12, 2025
Genmab has successfully acquired 94.2% of Merus N.V.'s outstanding shares at $97 per share, adding petosemtamab to its portfolio and positioning itself for potential billion-dollar revenue by 2029.
GlobeNewswire Inc. · Dec 3, 2025
Genmab A/S has completed a $2.5 billion notes offering, including $1.5 billion in senior secured notes and $1.0 billion in senior unsecured notes, to fund its acquisition of Merus N.V. and related expenses.
defenseworld.net · Dec 1, 2025
Ensign Peak Advisors Inc increased its stake in Merus N.V. (NASDAQ: MRUS) by 72.4% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,550 shares of the biotechnology company's stock after acquiring an additional 4,850 shares during
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MRUS.
No results
No recent SID articles mention MRUS.
